{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:16:52Z","timestamp":1788365812382,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jcv.2015.03.023","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T10:56:19Z","timestamp":1428231379000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Evaluation of the COBAS\u00ae AmpliPrep\/COBAS\u00ae TaqMan\u00ae HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study"],"prefix":"10.1016","volume":"67","author":[{"given":"Harald H.","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan R.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Michel-Treil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ceccherini-Nelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Helander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacene","family":"Khiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Heilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian O.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.03.023_bib0005","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0015","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0020","unstructured":"European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C, (2014). http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C\/index.html#p=I (accessed 10.03.15)."},{"key":"10.1016\/j.jcv.2015.03.023_bib0025","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/hep.24791","article-title":"Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment","volume":"55","author":"Harrington","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.03.023_bib0030","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.03.023_bib0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/hep.25516","article-title":"An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments","volume":"55","author":"Cobb","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.03.023_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.12544","article-title":"Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir","volume":"39","author":"Maasoumy","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jcv.2015.03.023_bib0045","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.03.023_bib0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/JCM.01784-12","article-title":"Second-generation Cobas AmpliPrep\/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design","volume":"51","author":"Zitzer","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.03.023_bib0055","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1128\/JCM.02004-12","article-title":"The Cobas AmpliPrep\/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA","volume":"51","author":"Chevaliez","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.03.023_bib0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/JCM.01729-12","article-title":"Performance evaluation of the new Roche cobas AmpliPrep\/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA","volume":"51","author":"Pas","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.03.023_bib0065","series-title":"Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline \u2013 Third Edition. CLSI Document EP09-A3 (ISBN 1-56238-887-8)","author":"Clinical Laboratory Standards Institute (CLSI)","year":"2013"},{"key":"10.1016\/j.jcv.2015.03.023_bib0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3851\/IMP2760","article-title":"HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy","volume":"19","author":"Fevery","year":"2014","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.jcv.2015.03.023_bib0075","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2014.01.002","article-title":"Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection","volume":"60","author":"Vermehren","year":"2014","journal-title":"J. Hepatol."},{"issue":"Suppl. 5","key":"10.1016\/j.jcv.2015.03.023_bib0080","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1016\/j.dld.2013.07.007","article-title":"The importance of HCV RNA measurement for tailoring treatment duration","volume":"45","author":"Peiffer","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jcv.2015.03.023_bib0085","doi-asserted-by":"crossref","first-page":"e110857","DOI":"10.1371\/journal.pone.0110857","article-title":"Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis","volume":"9","author":"Maasoumy","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2015.03.023_bib0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2013.05.002","article-title":"Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays","volume":"99","author":"Ogawa","year":"2013","journal-title":"Antiviral Res."},{"issue":"Jun 18","key":"10.1016\/j.jcv.2015.03.023_bib0095","article-title":"HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals","author":"Cloherty","year":"2014","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.jcv.2015.03.023_bib0100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0110","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0115","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.03.023_bib0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0125","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0130","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0135","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.03.023_bib0140","unstructured":"American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating hepatitis C, (2014). http:\/\/www.hcvguidelines.org\/full-report-view (accessed 10.03.15)."},{"key":"10.1016\/j.jcv.2015.03.023_bib0145","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.jcv.2015.03.023_bib0150","first-page":"1144A","article-title":"Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ABT-450\/r\/ombitasvir and dasabuvir with or without ribavirin","volume":"60","author":"Sulkowski","year":"2014","journal-title":"Hepatol"},{"issue":"S1","key":"10.1016\/j.jcv.2015.03.023_bib0155","first-page":"1132A","article-title":"On treatment HCV RNA as a predictor of virologic response in the ledipasvir\/sofosbuvir phase 3 program for HCV genotype 1 infection: analysis of the ION-1, ION-2, and ION-3 studies","volume":"60","author":"Welzel","year":"2014","journal-title":"Hepatol"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:09:51Z","timestamp":1761361791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":31,"alternative-id":["S1386653215001018"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.03.023","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the COBAS\u00ae AmpliPrep\/COBAS\u00ae TaqMan\u00ae HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}